MGRC’s cancer treatment options are not limited to just CAR T-Cell Immunotherapy. We also offer alternative immunotherapies that may be more suited for the patient’s cancer prognosis.
|IMMUNOTHERAPY GENE PRODUCT||TYPE OF CANCER|
|Tumour-Associated Antigen T-Cell (TAA-T) Therapy||
|T-Cell Receptor T-Cell (TCR-T) Therapy||
|Tumour-Infiltrating Lymphocyte (TIL) Therapy,
Short Chain Variable Fragment Immune Checkpoint
Inhibitors (scFv ICI)-PD-1, CD47
While chemotherapy and immunotherapy both aim to rid the human body of cancerous cells, the way two treatments work differ vastly. We’ve laid out the differences to encourage informed decisions for everyone.